The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes

New Drug Approvals

somatostatin receptor antagonist

C27 H23 F N8 O



1H-Pyrido[3,4-b]indole, 3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-2,3,4,9-tetrahydro-1-(5-methyl-1,2,4-oxadiazol-3-yl)-1-(1-methyl-1H-pyrazol-4-yl)-, (1R,3R)-


Merck & Co. (Originator)

Somatostatin srif1C (sst3) Antagonists

The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes 
(ACS Medicinal Chemistry Letters) Thursday May 10th 2012
Author(s): Shuwen HeZhixiong YeQuang TruongShrenik ShahWu DuLiangqin GuoPeter H. DobbelaarZhong LaiJian Liu,Tianying JianHongbo QiRaman K. BakshiQingmei HongJames DellureficioAlexander PasternakZhe FengReynalda deJesusLihu YangMikhail ReibarkhScott A. BradleyMark A. HolmesRichard G. BallRebecca T. RuckMark A. Huffman,Frederick WongKoppara SamuelVijay B. ReddyStan…

View original post 1,766 more words

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s